NOD2 and inflammatory bowel disease: g., compound heterozygous and homozygous carriers, were significantly younger at the first diagnosis of IBD (p = 0.010 and p = 0.036, respectively) than NOD2 wild-type carriers (“wild-type” defined as the absence of the three main NOD2 mutations.